-Program Update on its CDK2/9 Inhibitor, Oral Fadraciclib, and Oral PLK1 Inhibitor, CYC140, for the Treatment of Advanced Solid Tumors and Lymphoma-
-Monday, October 31st @ 10 am ET-
BERKELEY HEIGHTS, N.J., Oct. 24, 2022 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical firm growing revolutionary medicines primarily based on most cancers cell biology, at present introduced that it’s going to host a analysis and growth day, that includes key opinion leaders (KOL), with a concentrate on the Company’s CDK2/9 inhibitor, oral fadraciclib, and PLK1 inhibitor, oral CYC140, on Monday, October 31, 2022 at 10:00 am Eastern Time.
The R&D Day will function famend KOLs in oncology and program updates from senior administration.
- Jasmine Zain, MD, from City of Hope National Medical Center, can be offering an summary of the unmet medical wants within the therapy of T-cell lymphomas.
- Do-Youn Oh, MD, PhD, from Seoul National University, will talk about unmet medical wants and present therapy choices for hepatobiliary cancers.
The Cyclacel management crew will then present a program replace on the corporate’s pipeline, highlighting affected person knowledge from the 065-101 oral fadraciclib Phase 1/2 research in strong tumors and lymphoma. In addition, an replace will handle progress with CYC140, Cyclacel’s oral PLK1 inhibitor, in a Phase 1/2 research as a possible therapy for strong tumors and lymphoma.
A dwell Q&A session will comply with the formal displays. To register for the occasion, please click on right here.
Dr. Zain is a professor within the Department of Hematology & Hematopoietic Cell Transplantation and Director of the T cell Lymphoma Program on the Toni Stephenson Lymphoma Center at City of Hope since 2014. She has led many medical trials for T cell lymphomas and is a member of the NCCN Guidelines Committee for the therapy of T cell lymphomas.
Dr. Zain obtained her medical diploma from Fatima Jinnah Medical College for Women in Lahore, Pakistan. She went on to finish an internship and residency at North Shore Hospital, Forest Hills, NY, adopted by a hematology/oncology fellowship at New York University Medical Center. During her profession she has labored at many establishments together with Columbia University and NYU Medical Center. Her focus stays in growing novel therapies for T cell lymphomas.
Triple-board licensed in hematology, oncology and inside medication, Dr. Zain is an energetic member of a number of skilled associations and has printed greater than 78 peer-reviewed publications, abstracts and e-book chapters. She has been invited to talk each nationally and internationally.
Dr. Oh is Professor, Division of Medical Oncology, Department of Internal Medicine at Seoul National University and Seoul National University College of Medicine.
Dr. Oh graduated from Seoul National University College of Medicine in 1997, and had residency coaching in Internal Medicine, and a fellowship in Hematology/Medical Oncology coaching on the Seoul National University Hospital. She acquired her PhD within the Department of Internal Medicine on the Seoul National University College of Medicine in 2005.
Her predominant analysis pursuits embody gastric, pancreatic, and biliary tract most cancers, with a selected curiosity in translational analysis and early new drug growth. She has printed over 250 peer-reviewed journal articles and has many committee memberships, together with the Korean Cancer Association, Korean Association of Clinical Oncology, Korean Cancer Study Group, American Society of Clinical Oncology, and American Association for Cancer Research.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical firm growing revolutionary most cancers medicines primarily based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program CYC140, a PLK1 inhibitor, in sufferers with each strong tumors and hematological malignancies. Cyclacel’s technique is to construct a diversified biopharmaceutical business primarily based on a pipeline of novel drug candidates addressing oncology and hematology indications. For further data, please go to www.cyclacel.com.
Forward-looking Statements
This information launch incorporates sure forward-looking statements that contain dangers and uncertainties that would trigger precise outcomes to be materially completely different from historic outcomes or from any future outcomes expressed or implied by such forward-looking statements. Such forward-looking statements embody statements concerning, amongst different issues, the efficacy, security and supposed utilization of Cyclacel’s product candidates, the conduct and outcomes of future medical trials, plans concerning regulatory filings, future analysis and medical trials and plans concerning partnering actions. Factors which will trigger precise outcomes to vary materially embody the danger that product candidates that appeared promising in early analysis and medical trials don’t reveal security and/or efficacy in larger-scale or later medical trials, trials could have problem enrolling, Cyclacel could not acquire approval to market its product candidates, the dangers related to reliance on outdoors financing to fulfill capital necessities, the potential results of the COVID-19 pandemic, and the dangers related to reliance on collaborative companions for additional medical trials, growth and commercialization of product candidates. You are urged to contemplate statements that embody the phrases “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “forecast,” “designed,” “goal,” or the detrimental of these phrases or different comparable phrases to be unsure and forward-looking. For an additional listing and outline of the dangers and uncertainties the Company faces, please confer with our most up-to-date Annual Report on Form 10-Okay and different periodic and different filings we file with the Securities and Exchange Commission and can be found at www.sec.gov. Such forward-looking statements are present solely as of the date they’re made, and we assume no obligation to replace any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
Contacts
© Copyright 2022 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel brand and Cyclacel® are logos of Cyclacel Pharmaceuticals, Inc.
